Thymopoietin pentapeptide (TP-5) improves clinical parameters and lymphocyte subpopulations in atopic dermatitis
- 31 March 1983
- journal article
- clinical trial
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 8 (3) , 372-377
- https://doi.org/10.1016/s0190-9622(83)70042-3
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Enumeration of T cell subsets in atopic dermatitis using monoclonal antibodiesJournal of Allergy and Clinical Immunology, 1981
- Thymosin therapy in the DiGeorge syndromeThe Journal of Pediatrics, 1980
- Subpopulations of circulating B cells and regulatory T cells involved in in vitro immunoglobulin E production in atopic patients with elevted serum immunoglobulin E.Journal of Clinical Investigation, 1980
- Cell-mediated immunity and the in vitro effect of thymic humoral factor (THF) on blood lymphocytes of children with atopic dermatitisClinical Immunology and Immunopathology, 1980
- The in vitro effect of a calf thymus extract on the peripheral blood lymphocytes of patients with wartsBritish Journal of Dermatology, 1980
- A Synthetic Pentapeptide with Biological Activity Characteristic of the Thymic Hormone ThymopoietinScience, 1979
- Immune status in atopic eczema: a surveyBritish Journal of Dermatology, 1979
- Thymosin-inducible 'null' cells in atopic eczemaBritish Journal of Dermatology, 1979
- LONG‐TERM TRANSFER FACTOR TREATMENT IN SEVERE ATOPIC DERMATITISAllergy, 1977
- IN-VITRO DEMONSTRATION OF THYMIC HORMONE IN THE MOUSE BY CONVERSION OF PRECURSOR CELLS INTO LYMPHOCYTESThe Lancet, 1973